Our main focus: Common diseases such as asthma, allergies and chronic obstructive pulmonary disease (COPD), as well as infection-related inflammation of the lungs, in particular tuberculosis (TB).
19.11.2026
An international clinical research network has identified two drug combinations with the potential to substantially shorten the duration of tuberculosis treatment without compromising efficacy or tolerability. The findings have now been published in the internationally renowned New England Journal of Medicine.
12.11.2026
Over 130 participants, three internationally renowned keynote speakers and a lively industry exhibition: the 48th Northern Germany Meeting on Infection, Immunology & Inflammation (NDI3), held on 5 November 2026 at the FZB, was a resounding success.
11.11.2026
The Research Center Borstel, Leibniz Lung Center is a partner in a research project funded by the Novo Nordisk Foundation with 10 million Swedish kronor (approx. 900,000 €). The three year project, called SafeGM, aims to develop safer and more effective antibiotics against tuberculosis (TB).